Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Buy” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.43.

REPL has been the subject of a number of analyst reports. BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. HC Wainwright lifted their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. lifted their price target on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th.

Replimune Group Stock Down 6.7 %

Shares of NASDAQ REPL opened at $10.82 on Monday. The stock has a market cap of $833.30 million, a PE ratio of -3.52 and a beta of 1.30. The business has a fifty day moving average of $12.66 and a two-hundred day moving average of $12.14. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, equities research analysts expect that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the period. Graham Capital Management L.P. grew its position in shares of Replimune Group by 6.1% during the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after buying an additional 1,731 shares during the period. MetLife Investment Management LLC grew its position in shares of Replimune Group by 7.2% during the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock worth $456,000 after buying an additional 2,525 shares during the period. Algert Global LLC grew its position in shares of Replimune Group by 7.1% during the 4th quarter. Algert Global LLC now owns 45,820 shares of the company’s stock worth $555,000 after buying an additional 3,057 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Replimune Group by 24.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after buying an additional 3,177 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.